11.7 C
Addis Ababa
Friday, December 3, 2021
Bunna Bank Illustration teaser for web 2
Ethio telecom
previous arrow
next arrow
Shadow

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials

Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting. Further, the company releases new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program.
Over the next five years, as part of its commitment, Novartis will invest more than USD 100 million to advance research and development of next-generation treatments to combat emerging resistance to artemisinin and other currently used antimalarials.
The company will also implement an equitable pricing strategy to maximize patient access in malaria-endemic countries when these new treatments become available. In order to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90 percent by 2030, Novartis will further help expand access to pediatric antimalarials and implement healthcare system strengthening programs in 4 sub-Saharan countries.

Related Articles

Stay Connected

44,925FansLike
26,520FollowersFollow
124SubscribersSubscribe
- Advertisement -spot_img

Latest Articles